Cancer drug response prediction with surrogate modeling-based graph neural architecture search
Bioinformatics, ISSN: 1367-4811, Vol: 39, Issue: 8
2023
- 3Citations
- 8Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations3
- Citation Indexes3
- Captures8
- Readers8
Article Description
Motivation: Understanding drug-response differences in cancer treatments is one of the most challenging aspects of personalized medicine Recently, graph neural networks (GNNs) have become state-of-The-Art methods in many graph representation learning scenarios in bioinformatics However, building an optimal handcrafted GNN model for a particular drug sensitivity dataset requires manual design and fine-Tuning of the hyperparameters for the GNN model, which is time-consuming and requires expert knowledge Results: In this work, we propose AutoCDRP, a novel framework for automated cancer drug-response predictor using GNNs Our approach leverages surrogate modeling to efficiently search for the most effective GNN architecture AutoCDRP uses a surrogate model to predict the performance of GNN architectures sampled from a search space, allowing it to select the optimal architecture based on evaluation performance Hence, AutoCDRP can efficiently identify the optimal GNN architecture by exploring the performance of all GNN architectures in the search space Through comprehensive experiments on two benchmark datasets, we demonstrate that the GNN architecture generated by AutoCDRP surpasses state-of-The-Art designs Notably, the optimal GNN architecture identified by AutoCDRP consistently outperforms the best baseline architecture from the first epoch, providing further evidence of its effectiveness
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85168247034&origin=inward; http://dx.doi.org/10.1093/bioinformatics/btad478; http://www.ncbi.nlm.nih.gov/pubmed/37555809; https://academic.oup.com/bioinformatics/article/doi/10.1093/bioinformatics/btad478/7239861; https://dx.doi.org/10.1093/bioinformatics/btad478; https://academic.oup.com/bioinformatics/article/39/8/btad478/7239861
Oxford University Press (OUP)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know